The recently renamed BMP Sunstone Corporation (formerly Beijing Med-Pharm) reported that Propess® received a recommendation as the first-line treatment for labor induction in late-stage pregnancy. The recommendation came from the Obstetrics Group at the Obstetrics and Gynecology Branch of the Chinese Medical Association. BMP Sunstone began its efforts to sell and market Propess® in China in 2005, after licensing the drug from its manufacturer, Cytokine PharmaSciences, Inc. of Pennsylvania. More details...

Stock Symbol: (NSDQ: BJGP)